Conference Coverage
Conference Coverage
Novel SYK inhibitor shows ‘good early evidence’ of activity
LUGANO—The phase 1, first-in-human study of the novel SYK inhibitor TAK-659 is showing “good early evidence” of antitumor activity in patients...
Conference Coverage
‘Radically different’ PI3Kδ inhibitor lacks hepatotoxicity
Photo by Larry Young LUGANO—Updated phase 1 results with TGR-1202 suggest this next-generation PI3kδ inhibitor lacks the hepatotoxicity associated...
Conference Coverage
Targeted agent shows early promise for NHL
follicular lymphoma LUGANO—An anti-CD37 antibody-radionuclide conjugate provides sustained efficacy and a manageable safety profile in patients...
Conference Coverage
EZH2 inhibitor proves active in rel/ref NHL
LUGANO—The EZH2 inhibitor tazemetostat (EPZ-6438) has shown “meaningful clinical activity” as monotherapy in patients with advanced non-Hodgkin...
Conference Coverage
VIDEO: Ibrutinib should be therapy ‘backbone’ in relapsed CLL
Conference Coverage
EHA: Venetoclax-rituxumab combo highly active in relapsed/refractory CLL
Key clinical point: Venetoclax plus rituximab is a highly active nonchemotherapy combination for patients with relapsed or refractory chronic...
Conference Coverage
CAR T-cell therapy seems feasible for NHL, MM
©ASCO/Rodney White CHICAGO—The CD19-directed chimeric antigen receptor (CAR) T-cell therapy CTL019 has shown promise for treating non-Hodgkin...
Conference Coverage
Drug prolongs PFS in indolent, refractory NHL
the 2015 ASCO Annual Meeting CHICAGO—Adding obinutuzumab to treatment with bendamustine improves progression-free survival (PFS) in patients with...
Conference Coverage
Susceptibility to 2nd cancers in WM/LPL survivors
PHILADELPHIA—A retrospective study has revealed factors that appear to influence a person’s susceptibility to Waldenström’s macroglobulinemia (WM...
Conference Coverage
Maintenance prolongs PFS, not OS, in relapsed CLL
Credit: Linda Bartlett SAN FRANCISCO—Maintenance therapy with the anti-CD20 monoclonal antibody ofatumumab improves progression-free survival (PFS...